EXL CDOS
AssetAlso EXL CDOS (Ciprofloxacin 0.3% and Dexamethasone 0.1%) Sterile Otic Suspension
Topical antibacterial and anti-inflammatory combination of ciprofloxacin and dexamethasone.
- Stage
- Phase 3
- Modality
- Small molecule
- Target
- NR3C1
- 1
- Indication
- 2,129
- Trials
- 1
- Developer
Indications
1Acute otitis externa
Phase 3, Completed, NCT02216071, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains4
- Owner and partners1
- Trials2,129
- Evidence for its targets4
- Competitors12
- Signals3
Every asset’s record: target, stage, trials and the evidence behind it.